Skip to main content
4V Elevated logo4V ELEVATED
The 4V Journal

Emerging Research

Retatrutide: What the Clinical Program Shows

A careful look at an advancing clinical program: human trial findings, sponsor-reported results, and investigational status remain distinct.

Published
August 24, 2026
Last reviewed
August 22, 2026
Evidence context
Developing clinical evidence for an investigational subcutaneous drug. Peer-reviewed and sponsor-reported Phase III findings are labeled separately.

Research snapshot

Retatrutide is an investigational once-weekly drug that activates three receptors: GIP, GLP-1, and glucagon. That is why it is called a triple receptor agonist. It is sometimes nicknamed ‘GLP-3’ online, but there is no GLP-3 receptor involved.

In a peer-reviewed Phase III trial in adults with type 2 diabetes inadequately controlled with diet and exercise, retatrutide lowered A1C and produced substantial weight loss compared with placebo. The exact results belong to that studied population and regimen.

How to read the Phase III record

In sponsor-reported Phase III TRIUMPH-1 results, the 12 mg group averaged about 28.3% weight loss at 80 weeks under the efficacy estimand, with a prespecified extension reporting about 30.3% at 104 weeks in a higher-BMI subgroup. Those are trial averages, not predictions for an individual, and the obesity Phase III results should remain clearly labeled as sponsor/meeting-reported until the full peer-reviewed publication is available.

The most common adverse effects reported in retatrutide trials have been gastrointestinal, including nausea, diarrhea, constipation, and vomiting. Phase III reports have also described dose-related dysesthesia. Trial rates describe study populations and should not be converted into a personal risk estimate.

Investigational status and remaining limits

As of August 22, 2026, retatrutide remains investigational and is not approved by a regulatory agency. That status does not erase the positive Phase III evidence, and positive trials do not themselves equal approval. Regulatory status and scientific findings are related questions, but they are not the same question.

Separate-trial percentages do not prove that retatrutide is superior to tirzepatide. The trials differ in populations, duration, analysis methods, and protocols, and 4V has not identified a completed direct head-to-head trial supporting a simple superiority claim.

Continue in Research

Explore the matching structured Research Library topic and its selected source records.

Explore Retatrutide Research

Sources & references